Literature DB >> 19466518

Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction.

Yoshiro Naito1, Takeshi Tsujino, Masaaki Lee-Kawabata, Mika Matsumoto, Akira Ezumi, Shinji Nakao, Akiko Goda, Mitsumasa Ohyanagi, Tohru Masuyama.   

Abstract

Matrix metalloproteinases (MMPs) play important roles in progression of chronic heart failure (HF) by regulating cardiac extracellular matrix metabolism. However, there is no report to investigate the difference of circulating MMP-1 and MMP-2 levels between systolic HF (SHF) and diastolic HF (DHF), particularly in light of acute exacerbation of HF. We assessed 110 HF patients who were admitted because of an acute exacerbation. They were divided into two groups: SHF [n = 68, left ventricular ejection fraction (LVEF) <45%] or DHF (n = 42, LVEF > or =45%). Ten patients without HF served as controls. Serum MMP-1 and MMP-2, and plasma brain natriuretic peptide (BNP) levels were examined on admission and at discharge. Serum MMP-1 level was higher on admission in both SHF and DHF than in controls. It was higher in SHF than in DHF and did not change at discharge in both groups. Serum MMP-2 level was equally higher on admission in SHF and DHF than in controls. It decreased in both groups at discharge. Treatment-induced changes in LVEF and BNP level correlated with those in MMP-2 level in SHF but not in DHF. Circulating MMP-1 and MMP-2 levels showed different dynamics between SHF and DHF in acute exacerbation and after treatment. These differences in circulating MMP-1 and MMP-2 levels may be related to the phenotype of HF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19466518     DOI: 10.1007/s00380-008-1100-7

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  29 in total

Review 1.  Matrix metalloproteinases.

Authors:  H Nagase; J F Woessner
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

2.  Synergistic exacerbation of diastolic stiffness from short-term tachycardia-induced cardiodepression and angiotensin II.

Authors:  H Senzaki; Y A Gluzband; P H Pak; M T Crow; J S Janicki; D A Kass
Journal:  Circ Res       Date:  1998-03-09       Impact factor: 17.367

3.  ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography.

Authors:  M D Cheitlin; J S Alpert; W F Armstrong; G P Aurigemma; G A Beller; F Z Bierman; T W Davidson; J L Davis; P S Douglas; L D Gillam
Journal:  Circulation       Date:  1997-03-18       Impact factor: 29.690

Review 4.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

5.  Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy.

Authors:  Dimitrios N Tziakas; Georgios K Chalikias; Miltiadis Papaioakeim; Eleni I Hatzinikolaou; Dimitrios A Stakos; Ioannis K Tentes; Nikolaos Papanas; Alexandros Kortsaris; Efstratios Maltezos; Dimitrios I Hatseras
Journal:  Am J Cardiol       Date:  2005-09-29       Impact factor: 2.778

6.  Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.

Authors:  Jacob George; Shuki Patal; Dov Wexler; Arie Roth; David Sheps; Gad Keren
Journal:  Am Heart J       Date:  2005-09       Impact factor: 4.749

7.  Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure.

Authors:  Andrew T Yan; Raymond T Yan; Francis G Spinale; Rizwan Afzal; Himali R Gunasinghe; Malcolm Arnold; Catherine Demers; Robert S McKelvie; Peter P Liu
Journal:  J Card Fail       Date:  2006-09       Impact factor: 5.712

8.  Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function.

Authors:  F G Spinale; M L Coker; C V Thomas; J D Walker; R Mukherjee; L Hebbar
Journal:  Circ Res       Date:  1998-03-09       Impact factor: 17.367

9.  Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction.

Authors:  Takayuki Fujiwara; Toshiro Matsunaga; Kunihiko Kameda; Naoki Abe; Hirotsugu Ono; Takumi Higuma; Jin Yokoyama; Hiroyuki Hanada; Tomohiro Osanai; Ken Okumura
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

10.  Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction.

Authors:  Ramón Martos; John Baugh; Mark Ledwidge; Christina O'Loughlin; Carmel Conlon; Anil Patle; Seamas C Donnelly; Kenneth McDonald
Journal:  Circulation       Date:  2007-02-05       Impact factor: 29.690

View more
  10 in total

1.  Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril.

Authors:  Takashi Yokota; Tomohiro Osanai; Kenji Hanada; Motoi Kushibiki; Naoki Abe; Koichi Oikawa; Hirofumi Tomita; Takumi Higuma; Jin Yokoyama; Hiroyuki Hanada; Ken Okumura
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

2.  Force-frequency relationship as a predictor of long-term prognosis in patients with heart diseases.

Authors:  Komei Tanaka; Makoto Kodama; Masahiro Ito; Makoto Hoyano; Wataru Mitsuma; Mahmoud M Ramadan; Takeshi Kashimura; Satoru Hirono; Yuji Okura; Kiminori Kato; Haruo Hanawa; Yoshifusa Aizawa
Journal:  Heart Vessels       Date:  2010-10-27       Impact factor: 2.037

3.  Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients.

Authors:  Kana Wakabayashi; Takeshi Tsujino; Yoshiro Naito; Akira Ezumi; Masaaki Lee-Kawabata; Shinji Nakao; Akiko Goda; Yasushi Sakata; Kazuhiro Yamamoto; Takashi Daimon; Tohru Masuyama
Journal:  Heart Vessels       Date:  2010-11-10       Impact factor: 2.037

4.  High serum levels of thrombospondin-2 correlate with poor prognosis of patients with heart failure with preserved ejection fraction.

Authors:  Yuichi Kimura; Yasuhiro Izumiya; Shinsuke Hanatani; Eiichiro Yamamoto; Hiroaki Kusaka; Takanori Tokitsu; Seiji Takashio; Kenji Sakamoto; Kenichi Tsujita; Tomoko Tanaka; Megumi Yamamuro; Sunao Kojima; Shinji Tayama; Koichi Kaikita; Seiji Hokimoto; Hisao Ogawa
Journal:  Heart Vessels       Date:  2014-08-24       Impact factor: 2.037

5.  Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure.

Authors:  Tobias Täger; Clara Wiebalck; Hanna Fröhlich; Anna Corletto; Hugo A Katus; Lutz Frankenstein
Journal:  Clin Res Cardiol       Date:  2017-08-04       Impact factor: 5.460

6.  Dilatation of the ascending aorta and serum alpha 1-antitrypsin level in patients with bicuspid aortic valve.

Authors:  Kadriye Orta Kilickesmez; Okay Abaci; Cuneyt Kocas; Ahmet Yildiz; Aysem Kaya; Baris Okcun; Serdar Kucukoglu
Journal:  Heart Vessels       Date:  2011-06-23       Impact factor: 2.037

7.  Circulating matrix metalloproteinase patterns in association with aortic dilatation in bicuspid aortic valve patients with isolated severe aortic stenosis.

Authors:  Yongshi Wang; Boting Wu; Lili Dong; Chunsheng Wang; Xiaolin Wang; Xianhong Shu
Journal:  Heart Vessels       Date:  2014-10-18       Impact factor: 2.037

8.  Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure.

Authors:  Rachael Deardorff; Francis G Spinale
Journal:  Biomark Med       Date:  2009-10-01       Impact factor: 2.851

9.  Genetic variants associated with circulating MMP1 levels near matrix metalloproteinase genes on chromosome 11q21-22 in Taiwanese: interaction with obesity.

Authors:  Hsuan-Li Huang; Semon Wu; Lung-An Hsu; Ming-Sheng Teng; Jeng-Feng Lin; Yu-Chen Sun; Yu-Lin Ko
Journal:  BMC Med Genet       Date:  2013-03-04       Impact factor: 2.103

10.  Novel cardiac-specific biomarkers and the cardiovascular continuum.

Authors:  Efstathios Vassiliadis; Natasha Barascuk; Athanasios Didangelos; Morten A Karsdal
Journal:  Biomark Insights       Date:  2012-05-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.